Pharmacology & Therapeutics

Article	Citations
Editorial Board	462
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	434
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	379
Treatment strategies for leptomeningeal disease in patients with breast cancer	294
Unfolded protein responses: Dynamic machinery in wound healing	289
Editorial Board	252
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	222
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	216
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	209
Adenosine receptor signalling as a driver of pulmonary fibrosis	178
Matrikines in the skin: Origin, effects, and therapeutic potential	169
Treatment approaches for alcohol use disorder with metabolic dysfunction	130
The role of macrophages in asthma-related fibrosis and remodelling	128
Collateral lethality: A unique type of synthetic lethality in cancers	127
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	120
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	115
Inflammation, lipids, and pain in vulvar disease	113
Non-canonical G protein signaling	112
Endothelial dysfunction as a complication of anti-cancer therapy	99
SGLT2 inhibitors: Do they have antiarrhythmic properties?	95
Potential neonatal toxicity of new psychoactive substances	94
Editorial Board	93
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	93
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	90
TAAR1 as an emerging target for the treatment of psychiatric disorders	89

Management of drug-resistant hypertension as a heterogeneous disorder	89
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	87
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	86
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	84
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	83
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	81
Boron in cancer therapeutics: An overview	81
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	81
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	78
Review: Sex-related differences in the treatment of cardiac arrhythmia	77
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	77
Dysregulation of metabolic pathways in pulmonary fibrosis	77
Natural products that alleviate depression: The putative role of autophagy	75
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	75
Bispecific antibodies for the treatment of neuroblastoma	74
Editorial Board	73
Editorial Board	73
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	72
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	72
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	71
Pharmacological treatment of cardiogenic shock – A state of the art review	70
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
PGRMC1: An enigmatic heme-binding protein	70
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	68
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	67
Stabilizing the neural barrier – A novel approach in pain therapy	66
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	66
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	65
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	65
Insights into effective protocol structuring: optimizing dosing strategies, experimental design, and statistical approaches	65
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	63
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	63
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	63
Advances in pathogenesis and therapeutic strategies for osteoporosis	63
DNA methylation in cell plasticity and malignant transformation in liver diseases	63
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	61
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	60
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	57
Regulation of feeding and therapeutic application of bioactive peptides	57
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	56
Optimizing drug therapies in cardiac amyloidosis	55
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	55
The role of drug-metabolizing enzymes in synthetic lethality of cancer	55
Drug-induced Torsades de pointes: Insights from a canine model of chronic atrioventricular block	54
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	53
Therapeutic targeting of DNA methylation alterations in cancer	53
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	53
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	53
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	53

Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	52
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	52
Corrigendum to “Drug discovery through biophysical techniques: Methods and applications” [pharmacology and therapeutics volume 277 (2026) 108947]	52
Editorial Board	52
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	51
Editorial Board	51
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	51
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	51
Pharmacological potential of cyclic nucleotide signaling in immunity	51
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	50
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	50
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	50
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	50
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	49
CDNF and ER stress: Pharmacology and therapeutic possibilities	49
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	48
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	48
Organic anion transporters in remote sensing and organ crosstalk	48
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	48
MicroRNAs in drug addiction: Current status and future perspectives	48
Editorial Board	47
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	46
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	46
The role and participation of immune cells in the endometrial tumor microenvironment	46
G protein-coupled estrogen receptor biased signaling in health and disease	45
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	45
Oxidative stress and antioxidant therapeutic mechanisms	45
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	45
Exploring the landscape of post-translational modification in drug discovery	45
Molecular mechanisms of ferroptosis and their involvement in brain diseases	45
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	44
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	44
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation	44
Potential targeting of the tumor microenvironment to improve cancer virotherapy	43
Platelet lipid metabolism in vascular thrombo-inflammation	43
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	43
Understanding the molecular bridges between the drugs and immune cell	43
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	42
RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma	41
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	41
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	41
Mathematical modeling of T cell exhaustion in the tumor microenvironment	41
Targeting cell cycle checkpoints for glioma therapy	40
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	40
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	40
Prolactin and pain of endometriosis	40
Editorial Board	40
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	39
Plant-derived nanovesicles and therapeutic application	39
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	39
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	39
Early life adversities, psychopathologies and novel pharmacological strategies	39
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	38
From bench to clinic: Emerging therapies for corneal scarring	38
Editorial Board	37
The antidepressant actions of ketamine and its enantiomers	37
Editorial Board	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	37
Gene and stem cell therapy for inherited cardiac arrhythmias	37
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	37
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	36
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	36
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	36
Retina-directed gene therapy: Achievements and remaining challenges	36
Bile acids and neurological disease	35
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	35
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	35
Biased signaling in drug discovery and precision medicine	35
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	35
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	35
Anti-cancer activity of sustained release capsaicin formulations	35
Spotlight on plasticity-related genes: Current insights in health and disease	34
Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression	34
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	34
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?	34
Artificial intelligence with mass spectrometry-based multimodal molecular profiling methods for advancing therapeutic discovery of infectious diseases	33
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities	33
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy	33
A comprehensive review on pharmacokinetic mechanism of herb-herb/drug interactions in Chinese herbal formula	33

Clinical advances in oncolytic virotherapy for pediatric brain tumors	32
Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications	32
The free fatty acid receptor 2 (FFA2): Mechanisms of action, biased signaling, and clinical prospects	32
Targeting immunoproteasome in neurodegeneration: A glance to the future	32
Lessons learned from 20 years of preclinical testing in pediatric cancers	32
Mechanistic insights into medulloblastoma relapse	32
The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy	32
Human PSC-derived liver cells and their applications for disease models and drug discovery	31
“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)	31
Editorial Board	31
Resolution of inflammation in oral diseases	31
Formylpeptide receptors: A novel target to treat cardiometabolic complications	31
Next-generation nanocarriers for therapeutic oligonucleotides: Precision targeting and stimuli-responsive cancer therapy	31
Antithrombotic therapy following transcatheter aortic valve intervention	31
Editorial Board	31
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma	31
Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies	30
Potential application of natural compounds in ischaemic stroke: Focusing on the mechanisms underlying “lysosomocentric” dysfunction of the autophagy-lysosomal pathway	30
Advances in understanding cancer-associated neurogenesis and its implications on the neuroimmune axis in cancer	29
Novel therapeutic targets and drug discovery strategies in chronic obstructive pulmonary disease	29
A natural products solution to diabetic nephropathy therapy	29
PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications	29
Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies	29
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis	29
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases	29
From exploring cancer and virus targets to discovering active peptides through mRNA display	29
ThermoTRP channels in pain sexual dimorphism: new insights for drug intervention	29
Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols	28
Editorial Board	28
The future of targeted kinase inhibitors in melanoma	28
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders	28
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure	28
Editorial Board	28
CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control	27
Antiviral drug repurposing: different approaches and the case of antifungal drugs	27
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics	27
The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans	27
The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine	27
The role of MyD88 in the nervous system: Neuronal functions, implications in neurological diseases, and therapeutic potential	27
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease	27
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?	26
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies	26
Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions	26
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response	26
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis	26
Editorial Board	25
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer	25
Novel strategies exploiting interleukin-12 in cancer immunotherapy	25
Editorial Board	25
The many facets of biased signaling: Mechanisms and possible therapeutic implications	25
Inflammation in kidney repair: Mechanism and therapeutic potential	25
Editorial Board	25
The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges	25
Overview of the role of purinergic signaling and insights into its role in cancer therapy	25
Targeting selective autophagy in CNS disorders by small-molecule compounds	24
Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target	24
Improvement of chronic metabolic inflammation and regulation of gut homeostasis: Tea as a potential therapy	24
Understanding the physiological role of NaV1.9: Challenges and opportunities for pain modulation	24
Endothelial progenitor cells in the host defense response	24
Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy	23
Glyoxalase I is a novel target for the prevention of metabolic derangement	23
Cancer metastasis: Molecular mechanisms and clinical perspectives	23
Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring	23
Potassium homeostasis – Physiology and pharmacology in a clinical context	23
The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?	23
Corrigendum to “Game of clones: Battles in the field of carcinogenesis” [Pharmacology & Therapeutics, volume 237, Pages 108–251]	22
Small molecules as a source for acute kidney injury therapy	22
Pathological and pharmacological functions of the metabolites of polyunsaturated fatty acids mediated by cyclooxygenases, lipoxygenases, and cytochrome P450s in cancers	22
Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors	22
Mass spectrometry-based absolute quantitative proteomics of drug-metabolizing enzymes in human liver	22
Biased signaling by human follicle-stimulating hormone variants	22
Neuroimmune modulators derived from natural products: Mechanisms and potential therapies	22
Inflammation and oxidative stress as mediators of the impacts of environmental exposures on human pregnancy: Evidence from oxylipins	21
Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension	21
Current drug treatment methods and potential significance of glucocorticoid for inoperable advanced thymoma	21
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors	21
Impact of G protein-coupled receptor conformation on signaling bias: Integrating simulations and biophysical experiments	21
The controversial role of beta-blockers in heart failure with preserved ejection fraction	21
Biased agonism in peptide-GPCRs: A structural perspective	20
Preface to the Special Issue	20
Terpenes: Modulating anti-inflammatory signaling in inflammatory bowel disease	20
Semaphorin 3s signaling in the central nervous system: Mechanisms and therapeutic implication for brain diseases	20
What matters in aging is signaling for responsiveness	20
Detailed curriculum vitae of HER2-targeted therapy	20
Editorial Board	20
Neurobiology of cancer: Adrenergic signaling and drug repurposing	20
Editorial Board	20
Drug discovery through biophysical techniques: Methods and applications	20
Targeting organ-specific mitochondrial dysfunction to improve biological aging	20
The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment	20
NETosis in ischemic stroke: Mechanisms, implications, and therapeutic prospects	20
Antibody drug conjugates: The dos and don'ts in clinical development	19
Superconserved receptors expressed in the brain: Expression, function, motifs and evolution of an orphan receptor family	19
ALDH2 polymorphism and myocardial infarction: From alcohol metabolism to redox regulation	19
Multitarget antibacterial drugs: An effective strategy to combat bacterial resistance	19